Trexquant Investment LP Increases Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

Trexquant Investment LP grew its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 29.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 221,262 shares of the company’s stock after acquiring an additional 50,635 shares during the period. Trexquant Investment LP owned 0.15% of MiMedx Group worth $2,129,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. IMG Wealth Management Inc. bought a new position in MiMedx Group in the 4th quarter worth $28,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the fourth quarter worth about $40,000. Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% during the 3rd quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after buying an additional 4,275 shares in the last quarter. Orion Capital Management LLC grew its stake in shares of MiMedx Group by 46.3% during the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after acquiring an additional 3,700 shares during the period. Finally, SkyView Investment Advisors LLC increased its holdings in MiMedx Group by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after acquiring an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

MDXG opened at $6.86 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 12.47 and a beta of 1.74. The company has a fifty day moving average of $7.99 and a 200 day moving average of $7.97. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The firm had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, sell-side analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MDXG shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 4th.

Insider Transactions at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the sale, the chief accounting officer now directly owns 440,178 shares of the company’s stock, valued at $3,473,004.42. This trade represents a 11.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock valued at $1,130,312 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.